Touchstone Innovations’ (IVO) portfolio continues to grow – net portfolio value rose by £47.7m to £382.8m, mainly driven by investments of £29.0m across 18 companies (vs £27.5m in 17 companies in H116) and a fair value gain of £26.5m (mainly from a £21.9m uplift in the value of PsiOxus). Four new additions to the portfolio across both tech and healthcare, and the advancement of projects in both the UCL technology fund and Apollo Therapeutics, continue to strengthen the early-stage pipeline. We anticipate major deal activity to drive further value in the next 12 months.
Written by
Touchstone Innovations |
Strong deal flow highlights maturing portfolio |
Interim results |
Pharma & biotech |
4 April 2017 |
Share price performance
Business description
Next events
Analysts
Touchstone Innovations is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Touchstone Innovations’ (IVO) portfolio continues to grow – net portfolio value rose by £47.7m to £382.8m, mainly driven by investments of £29.0m across 18 companies (vs £27.5m in 17 companies in H116) and a fair value gain of £26.5m (mainly from a £21.9m uplift in the value of PsiOxus). Four new additions to the portfolio across both tech and healthcare, and the advancement of projects in both the UCL technology fund and Apollo Therapeutics, continue to strengthen the early-stage pipeline. We anticipate major deal activity to drive further value in the next 12 months.
Year end |
Net portfolio value* (£m) |
Cash** (£m) |
Net fair value gain (£m) |
Net asset value (£m) |
NAV/share (p) |
DPS (p) |
07/15 |
327.2 |
128.1 |
21.3 |
420.1 |
306 |
0.0 |
07/16 |
335.1 |
148.3 |
(56.2) |
455.9 |
283 |
0.0 |
07/17e |
436.2 |
116.3 |
30.0 |
472.3 |
293 |
0.0 |
07/18e |
537.4 |
26.4 |
30.0 |
491.5 |
305 |
0.0 |
Note: *Net value, excludes provisions. **Cash, cash equivalents and short-term investments.
PsiOxus takes the driving seat
Following the uplift in carrying value of PsiOxus Therapeutics to £44.5m (as a result of its $936m [$50m upfront] deal with Bristol Myers Squib [BMS]), it is now the largest single constituent of IVO’s portfolio and represents a significant 325% uplift on the £13.7m (26.5% of issued share capital) invested to date. Along with Nexeon (invested £27.4m, carrying value £41.9m) and Veryan Medical (invested £22.1m, carrying value £29.3m), the top three companies represent 30.2% of total portfolio value (60.9% of the total portfolio value is in the top 10 companies).
Post-period portfolio news to lift valuations
March 2017 newsflow should further lift fair valuations. IVO more than doubled its investment in Cell Medica with £13.7m into the recent £60m Series C round; committed £3m to Pulmocide’s £25m Series B; and its £3.85m commitment to Garrison’s £12m funding round will crystallise a c £3m net fair value gain. Circassia’s strategic respiratory collaboration with AstraZeneca boosted its carrying value by c £4m compared to end-H117 (£23.6m vs £27.8m as of 04th April).
Financials: H117
A pre-tax profit in H117 of £16.0m (H116: loss of £5.9m) was driven by gains in the quoted (£3.4m gain) and unquoted portfolio (£23.1m). Gains in quoted were mainly driven by the sale of Oxford Immunotec (£11.3m in total, £3.8m attributable to H1), while the unquoted was driven by the £21.9m fair value gain of PsiOxus. These were partially offset by a fair value loss of £8.4m, mainly driven by the £6.2m write-down of Kesios Therapeutics after the failure of its underlying technology. Cash at 31 January stood at £113.3m (not including drawdown of the £50.0m EIB loan).
Valuation: Maturing pipeline yet to be reflected
IVO’s shares trade at a c 12.5% premium to our estimated FY17e NAV of 293p/share (at 1 April 2016). We believe this is a modest premium based on the growing maturity of the portfolio and we see near-term potential for uplifts in value.
Exhibit 1: Financial summary
£'000s |
2014 |
2015 |
2016 |
2017e |
2018e |
||
Year end 31 July |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|
|
|
|
|
|
|
Revenue |
|
|
3,636 |
5,099 |
4,257 |
4,359 |
4,463 |
Cost of sales |
|
|
(1,005) |
(1,769) |
(1,395) |
(1,396) |
(1,438) |
Gross profit |
|
|
2,631 |
3,330 |
2,862 |
2,963 |
3,025 |
EBITDA |
|
|
(8,385) |
(8,223) |
(9,758) |
(10,289) |
(10,890) |
Operating profit (before GW and except.) |
(8,418) |
(8,237) |
(9,772) |
(10,303) |
(10,904) |
||
Fair value gains/losses |
|
|
40,549 |
21,324 |
(56,249) |
30,000 |
30,000 |
Impairments |
|
|
0 |
0 |
0 |
0 |
0 |
Share-based payment |
|
|
(4,821) |
1,161 |
2,972 |
(3,000) |
(3,000) |
Operating profit |
|
|
27,310 |
14,248 |
(63,049) |
16,697 |
16,096 |
Net interest |
|
|
106 |
817 |
(64) |
(680) |
(741) |
Profit before tax (norm) |
|
|
(8,312) |
(7,420) |
(9,836) |
(10,983) |
(11,645) |
Profit before tax (FRS 3) |
|
|
27,416 |
15,065 |
(63,113) |
16,017 |
15,355 |
Tax |
|
|
0 |
0 |
0 |
0 |
0 |
Profit after tax (norm) |
|
|
(8,312) |
(7,420) |
(9,836) |
(10,983) |
(11,645) |
Profit after tax (FRS 3) |
|
|
27,416 |
15,065 |
(63,113) |
16,017 |
15,355 |
Average number of shares outstanding (m) |
|
102.4 |
136.2 |
146.1 |
161.2 |
161.2 |
|
EPS - normalised (p) |
|
|
(8.1) |
(5.4) |
(6.7) |
(6.8) |
(7.2) |
EPS - reported (p) |
|
|
26.8 |
11.1 |
(43.2) |
9.9 |
9.5 |
Dividend per share (p) |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
BALANCE SHEET |
|
|
|
|
|
|
|
Fixed assets |
|
|
258,327 |
333,936 |
345,615 |
440,839 |
542,038 |
Tangible assets |
|
|
26 |
29 |
18 |
1,081 |
1,092 |
Intangible assets |
|
|
0 |
0 |
0 |
0 |
0 |
Investment Portfolio |
|
|
257,105 |
333,268 |
345,146 |
439,094 |
540,282 |
UCSF (University Challenge Seed Fund) investments |
543 |
460 |
163 |
163 |
163 |
||
UCSF loans |
|
|
0 |
0 |
0 |
0 |
0 |
Other |
|
|
653 |
179 |
288 |
501 |
501 |
Financial asset |
|
|
0 |
0 |
0 |
0 |
0 |
Current assets |
|
|
177,800 |
130,506 |
152,792 |
120,859 |
31,067 |
Cash and cash equivalents |
|
|
176,462 |
128,097 |
148,306 |
116,266 |
26,364 |
Financial asset |
|
|
0 |
0 |
0 |
0 |
0 |
Accounts receivable, net |
|
|
1,338 |
2,409 |
4,486 |
4,593 |
4,703 |
Current liabilities |
|
|
(4,900) |
(5,732) |
(7,333) |
(7,333) |
(7,333) |
Trade accounts payable |
|
|
(4,900) |
(4,232) |
(4,166) |
(4,166) |
(4,166) |
Short-term borrowings |
|
|
0 |
(1,500) |
(3,167) |
(3,167) |
(3,167) |
Long-term liabilities |
|
|
(26,445) |
(38,639) |
(35,184) |
(82,103) |
(74,263) |
Long-term borrowings |
|
|
(14,830) |
(27,222) |
(24,089) |
(71,680) |
(64,512) |
UCSF |
|
|
(640) |
(666) |
(477) |
(477) |
(477) |
Provisions |
|
|
(10,975) |
(10,751) |
(10,618) |
(9,946) |
(9,274) |
Net assets |
|
|
404,782 |
420,071 |
455,890 |
472,262 |
491,509 |
NAV/share (p) |
|
|
295 |
306 |
283 |
293 |
305 |
CASH FLOW |
|
|
|
|
|
|
|
Operating cash flow |
|
|
(6,523) |
(9,331) |
(10,799) |
(10,182) |
(10,780) |
Net Interest |
|
|
44 |
875 |
(24) |
(680) |
(741) |
Tax |
|
|
0 |
0 |
0 |
0 |
0 |
Capex |
|
|
(23) |
(17) |
0 |
(1,077) |
(25) |
Purchase of trade investments |
|
|
(32,826) |
(59,957) |
(71,046) |
(71,117) |
(71,188) |
Proceeds from sale of trade investments |
|
|
3,370 |
7,179 |
4,979 |
7,169 |
0 |
Revenue share paid on asset realisations in trade investments |
|
|
0 |
(989) |
0 |
(3,745) |
0 |
Equity financing |
|
|
146,823 |
0 |
98,599 |
0 |
0 |
Short term liquidity investments |
|
|
0 |
0 |
0 |
0 |
0 |
Net cash flow |
|
|
110,865 |
(62,240) |
21,709 |
(79,632) |
(82,734) |
Opening net debt/(cash) |
|
|
(50,783) |
(161,632) |
(99,375) |
(121,050) |
(41,418) |
Other |
|
|
(16) |
(17) |
(34) |
0 |
0 |
Closing net debt/(cash) |
|
|
(161,632) |
(99,375) |
(121,050) |
(41,418) |
41,315 |
Source: Touchstone Innovations, Edison Investment Research.
|
|
Research: Investment Companies
Fidelity China Special Situations (FCSS) was launched in April 2010 aiming to generate long-term capital growth from investing in Chinese companies or companies that generate the majority of their revenues in China. Manager Dale Nicholls invests for the long term, seeking companies with long-term growth potential that are trading at reasonable valuations. FCSS’s NAV and share price absolute total returns have been very strong over the last 12 months, and the trust has meaningfully outperformed the index over one, three and five years and since the fund’s inception. FCSS has also outperformed the majority of its open- and closed-ended peers over one, three and five years.